Advanced Refractive predicts first-quarter 2007 launch for novel cataract emulsifier:
This article was originally published in Clinica
Executive Summary
Advanced Refractive Technologies believes it could be set to file later this year a US marketing application for its next-generation cataract emulsifier. Its Accupulse device is novel in that it combines water-jet and ultrasound technologies, the company claims. Accupulse is to undergo animal studies designed to optimise the final design characteristics of the product and to prepare the device for FDA 510(k) approval. A 510(k) filing could be completed in the fourth quarter of 2006, with approval and initial sales occurring during the first quarter 2007, said Randy Bailey, the San Clemente, California firm's president and CEO. Around 18 million cataract surgeries are forecast for 2007, the company added.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.